Non-opioid Analgesia for Fast-track Surgery
Information source: McGill University Health Center
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain
Intervention: Esmolol (Drug); Remifentanil (Drug)
Phase: N/A
Status: Completed
Sponsored by: McGill University Health Center Official(s) and/or principal investigator(s): Gabriele Baldini, MD, Principal Investigator, Affiliation: McGill University Health Center
Summary
In this randomized observer-blinded trial the analgesic efficacy of intravenous esmolol, as
alternative to intraoperative opioids, is tested in patients undergoing laparoscopic
prostatectomy and upper gastrointestinal surgery (such as Nissen fundoplication). The
purpose of this study is to determine whether intravenous esmolol improves postoperative
analgesia and accelerate the surgical recovery. We hypothesize that patients receiving
intravenous esmolol will consume less analgesic in the postoperative period, will have less
opioid-related side effects and will recover their functional status faster then patients
receiving intravenous esmolol.
Patients will be stratified according to the type of surgical procedure in 2 arms: 40
patients with prostate cancer and undergoing elective laparoscopic prostatectomy, and 40
patients with gastro-esophageal reflux undergoing upper gastrointestinal surgery (Nissen
funduplication) will be enrolled.
Patients will receive total intravenous anesthesia with propofol and esmolol (Esmolol group,
n=20 in each arm) or propofol and remifentanil (Remifentanil Group, n=20 in each arm).
Clinical Details
Official title: Fast-track Laparoscopic Surgery. The Effect of Anesthetic Technique
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Amount of postoperative opioid consumption
Secondary outcome: Postoperative pain intensityIncidence of opioids side-effects Length of stay in the PACU Length of stay in the hospital CHAMPS questionnaire short-term SF-36 2 minutes walking test 6 minutes walking test
Detailed description:
Outcomes:
1. Primary: The amount of fentanyl needed in PACU and the amount of PCA morphine used
during the first 24 postoperative hours.
2. Secondary: intensity of postoperative pain (visual analogue scale,VAS), opioids side
effects, length of stay in PACU and in the hospital, short-term SF-36 questionnaire,
CHAMPS questionnaire, and the 2 and 6 minutes walking tests.
Methodology:
In each arm patients will be assigned by computer generated random letters to two groups:
The Esmolol group: patients will receive no opioids but will receive esmolol at induction
and as a continuous infusion during the surgery.
The Remifentanil group: patients will receive remifentanil as sole opioid during induction
of anesthesia as a continuous infusion during the surgery.
During the preoperative assessment patients will be asked to fill out the CHAMPS and the
Short-term SF-36 questionnaires. The 2 and 6 minutes walking tests will be also administered
On arrival in the operating room, routine monitors will be applied for recording heart rate,
systolic blood pressure, and oxygen saturation. In addition, the electroencephalographic
bispectral index (BIS) value was obtained using a single channel sensor in a frontal
temporal area. The BIS is a standard monitor of depth of anesthesia and measures cortical
activation. It has been found to be well correlated to electroencephalogram. After obtaining
baseline values, midazolam 1-2mg IV will be administered for pre-medication. Anesthesia
will be subsequently induced with Propofol 2-2. 5 mg/kg, Rocuronium 0. 45-0. 9 mg/kg.
The Esmolol group will receive 1. 0 mg/kg of esmolol and the Remifentanil group 1. 0 mcg/kg
of remifentanil for induction of anesthesia. After direct laryngoscopy and tracheal
intubation will have been performed, anesthesia will be maintained with a continuous
infusion of propofol 80-250 mcg/kg/min to maintain a "targeted" BIS value of 50 or less (BIS
below 60 signifies the patient is asleep and unaware, 90 and over signifies intraoperative
wakefulness). Patients will receive either esmolol infusion of 5-15 mcg/kg/min or
remifentanil infusion of 0. 025-0. 25mcg/kg/min (in Esmolol group or in the Remifentanil group
respectively) titrated to maintain HR within 25% of the pre-induction baseline value with
targeted HR in between 55-90. Furthermore, the patients will also receive IV fluid at 6
ml/kg. All patients will be mechanically ventilated to maintain the end-tidal carbon
dioxide (CO2) concentration in the range of 36-44 mm Hg and will receive toward the end of
surgery Ketorolac 30mg IV, Droperidol 0. 625mg IV and neuromuscular reversal if needed.
Propofol will be discontinued after the last skin suture and the remifentanil or esmolol
infusions will be stopped. After closure 10cc of bupivacaine 0. 25% with epinephrine
1: 200. 000 will be infiltrated in the surgical ports. Nurses in the PACU will be informed
that patients are taking part of the study but will not be aware of the hypothesis and will
provide patients with standard care. Patients will have access in PACU to Fentanyl 25mcg IV
q5min and to Ondansetron 2-8mg IV prn (standard medications used in this institution).
Patients will receive PCA morphine for 24-48 h with tylenol 650mg PO q4h and naproxen 500mg
or celebrex 200 mg PO bid.
Heart rate, blood pressure, BIS and oxygen saturation will be recorded at baseline,
induction of anesthesia, tracheal intubation, skin incision, and subsequently at 5 min
intervals until the end of surgery. Patients will be extubated in the operating room. They
will then be transported to the post anesthesia care unit (PACU).
Assessment:
Recovery time will be assessed by a blinded observer (research fellow) unaware of the study
hypothesis from the time the study drugs are discontinued. Times to awakening (opening eyes
on verbal command), and orientation to person, date and place will be recorded, whereas the
time to home readiness will be evaluated using standardized discharge criteria as described
by White-Song17 at 30 min intervals. The score maximum of 12 out of 14 allows the patients
to be discharged to the surgical ward from the PACU. Pain will be assessed every 15 minutes
using (visual analog scale) (VAS)18 (0-10 cm) at rest, on movements and on coughing by the
recovery nurse. Postoperative side effects (nausea, vomiting, pain), requirement for
analgesics and antiemetics therapy (morphine and zofran respectively), as well as patient
satisfaction will be assessed on discharge from PACU and 24-48 hrs after the procedure.
Eligibility
Minimum age: 18 Years.
Maximum age: 85 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Patients with prostate cancer undergoing laparoscopic prostatectomy
2. Patients with gastro-esophageal reflux undergoing upper abdominal surgery (Nissen
funduplication)
Exclusion Criteria:
1. Age <18 yr or > 85 yr
2. ASA physical status 3 and greater
3. History of hepatic failure (Child & Pug A-C)
4. Renal failure (creatinine outside the normal range)
5. Cardiac failure (NYHA I-IV)
6. Organ transplant
7. Diabetes mellitus type 1 and 2
8. Morbid obesity (BMI > 40)
9. Chronic use of opioids and beta-blockers
10. Severe mental impairment
11. History of allergic reactions to all the medications used in the study or inability
to understand pain assessment.
12. Asthma or Reactive airway disease
13. Patient with known or suspected peritoneal adhesion
14. Pregnancy
Locations and Contacts
Montreal General Hospital, McGill University Health Centre, Montreal, Quebec H3G1A4, Canada
Additional Information
Starting date: January 2009
Last updated: March 25, 2013
|